From the Department of Respiratory Medicine Second Ward (Hao), JinanThird People's Hospital, Jinan, from the Department of Cadre Healthcare/Geriatrics (Lu), Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, from the Hebei North University (Guo), Zhangjiakou, and from the Department of Pulmonary and Critical Care Medicine (Bao), The Eighth Medical Center of Chinese PLA General Hospital, Beijing, China.
Saudi Med J. 2024 Aug;45(8):783-790. doi: 10.15537/smj.2024.45.8.20230990.
To identify biomarkers that can discriminated small cell lung cancer (SCLC) from non-SCLC (NSCLC), and explore their association with the prognosis of SCLC under chemoradiotherapy.
The GSE40275 dataset was used to identify potential targets in SCLC. There were 196 patients of lung cancer (LC) in cohort 1 of this study. levels in tissues were determined by immunohistochemistry assay in cohort 1. Lung cancer patients who were all underwent local chemoradiotherapy (CRT) were included in cohort 2, and the association of levels with CRT treatment outcome were determined in cohort 2. Cell experiments were used to determine the function of on the radio-sensitivity of SCLC and NSCLC cells.
The levels in LC tissues were increased, and could discriminate SCLC from both lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD). Small cell lung cancer patients with high phenotype had a poorer prognosis after CRT treatment, whereas no significant correlation was found between levels and prognosis in LUSC and LUAD group. Cell experiments demonstrated that overexpression of increases radio-resistance in both SCLC and NSCLC in vitro.
expressions might be a novel specifically prognostic biomarker for SCLC and the CRT treatment outcome.
寻找可区分小细胞肺癌（SCLC）与非小细胞肺癌（NSCLC）的生物标志物，并探讨其与 SCLC 患者接受放化疗后预后的关系。
本研究使用 GSE40275 数据集来鉴定 SCLC 中的潜在靶点。在队列 1 中，共有 196 名肺癌患者。队列 1 中采用免疫组化检测组织中 水平。所有接受局部放化疗（CRT）的肺癌患者均纳入队列 2，并在队列 2 中确定 水平与 CRT 治疗结果的关系。细胞实验用于确定 对 SCLC 和 NSCLC 细胞放射敏感性的作用。
LC 组织中 水平升高，可区分 SCLC 与肺鳞癌（LUSC）和肺腺癌（LUAD）。CRT 治疗后，高表达 表型的 SCLC 患者预后较差，而在 LUSC 和 LUAD 组中， 水平与预后之间无明显相关性。细胞实验表明， 过表达可增加 SCLC 和 NSCLC 细胞的体外放射抗性。
表达可能是 SCLC 的一种新型特异性预后生物标志物，与 SCLC 患者 CRT 治疗结果相关。
